Phase I clinical study with 5 peptides vaccination in HLA-A2402-positive advanced-stage esophageal cancer patients
Phase 1
- Conditions
- chemotherapy-resistance unresectable esophageal cancer
- Registration Number
- JPRN-UMIN000004714
- Lead Sponsor
- Tokai University school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Not provided
Exclusion Criteria
1)severe comorbidity(cardiovascular disease, respiratory disease, infectious disease) 2)pregnant woman 3)systemic administration of immunosuppressant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method